Scarica l'app Stockscreener
67.42
0.84%
0.56
Dopo l'orario di chiusura:
67.16
-0.26
-0.39%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$66.86
Aprire:
$66.92
Volume 24 ore:
948.10K
Relative Volume:
0.16
Capitalizzazione di mercato:
$26.29B
Reddito:
$4.30B
Utile/perdita netta:
$571.50M
Rapporto P/E:
47.20
EPS:
1.4285
Flusso di cassa netto:
$570.80M
1 W Prestazione:
+2.54%
1M Prestazione:
+8.37%
6M Prestazione:
-23.01%
1 anno Prestazione:
-15.98%
Intervallo 1D:
$66.75
$67.51
Intervallo di 1 settimana:
$65.56
$67.95
Portata 52W:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
67.42 | 26.08B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
124.81 | 216.56B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.13 | 142.45B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.74 | 135.69B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.27 | 124.96B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
86.29 | 50.04B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PR Newswire
DexCom, Inc. (DXCM) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of December 26, 2025 Deadline - Stockhouse
DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc.(DXCM) Shareholders - The Malaysian Reserve
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Lost Money on DexCom, Inc. (DXCM)? Join Class Action Before December 26, 2025Contact Levi & Korsinsky - ACCESS Newswire
DexCom, Inc. $DXCM Shares Sold by Congress Asset Management Co. - MarketBeat
Dexcom G6 Continuous Glucose Monitoring (CGM) Lawsuit - Drugwatch.com
DexCom, Inc. (DXCM) Announces Leadership Transition with New CEO Appointment - GuruFocus
Dexcom Names Jacob Leach as Incoming Chief Executive - TipRanks
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom Inc Announces CEO Appointment - TradingView — Track All Markets
Shareholders SueWallSt in New Class Action Against DexCom, Inc.Act Now - Nasdaq
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Levi & Korsinsky Urges DexCom (DXCM) Shareholders to Act Before Lead Plaintiff Deadline December 26, 2025 - ACCESS Newswire
Morgan Stanley Upgrades DexCom (DXCM), Cites Undervalued Recovery and G7 Margin Potential - Insider Monkey
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DexCom, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm for More InformationDXCM - PR Newswire
What sentiment indicators say about DexCom Inc. stockQuarterly Profit Review & AI Enhanced Trading Signals - ulpravda.ru
Important December 26, 2025 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Investors of Securities Fraud Class Action Lawsuit - The Malaysian Reserve
Zevenbergen Capital Investments LLC Purchases 62,098 Shares of DexCom, Inc. $DXCM - MarketBeat
Is DexCom Inc. stock supported by strong cash flowsJuly 2025 Trends & Smart Money Movement Tracker - Улправда
Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations - Nasdaq
Will DexCom Inc. stock sustain high P E ratios2025 Key Lessons & Reliable Entry Point Trade Alerts - ulpravda.ru
DXCM STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Will DexCom Inc. stock benefit from sector rotationJuly 2025 Snapshot & Low Drawdown Trading Techniques - DonanımHaber
Dexcom (DXCM) Gets a Buy from Canaccord Genuity - The Globe and Mail
Levi & Korsinsky Reminds DexCom, Inc. Investors of the - GlobeNewswire
Investors in DexCom (NASDAQ:DXCM) have unfortunately lost 43% over the last three years - Yahoo Finance
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. InvestorsLead Plaintiff Deadline December 26, 2025 - ACCESS Newswire
Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
DXCM DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Dexcom, Inc. (DXCM) Securities Fraud Class Action Lawsuit - NewMediaWire
DexCom, Inc. (DXCM) Shareholders Get Answers in Latest SueWallSt Podcast - ACCESS Newswire
Meme Stocks: What sentiment indicators say about DexCom Inc. stockGap Down & Community Verified Trade Signals - ulpravda.ru
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DexCom (DXCM) Fell Due to Modest Guidance - Insider Monkey
DexCom, Inc. Class Action: The Gross Law Firm Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025DXCM - marketscreener.com
Sendero Wealth Management LLC Has $4.54 Million Position in DexCom, Inc. $DXCM - MarketBeat
Thrivent Financial for Lutherans Lowers Holdings in DexCom, Inc. $DXCM - MarketBeat
Dexcom (DXCM): Valuation Check After Launch of Dexcom Academy for EMEA Healthcare Professionals - Sahm
Assenagon Asset Management S.A. Cuts Stock Position in DexCom, Inc. $DXCM - MarketBeat
DexCom (NASDAQ:DXCM) Given New $78.00 Price Target at Mizuho - Defense World
Mizuho Maintains DexCom (DXCM) Outperform Recommendation - Nasdaq
DexCom, Inc. $DXCM Shares Bought by Gradient Investments LLC - Defense World
Investors who lost money on DexCom, Inc.(DXCM) should - GlobeNewswire
Class Action Lawsuit Filed Against DexCom, Inc. (DXCM)Recover LossesContact Levi & Korsinsky Before December 26, 2025 - ACCESS Newswire
Key facts: Class action lawsuit filed against DexCom; Mizuho raises price target - TradingView — Track All Markets
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now - The Globe and Mail
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (NASDAQ: DXCM) - GlobeNewswire
Mizuho Issues Positive Forecast for DexCom (NASDAQ:DXCM) Stock Price - MarketBeat
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):